Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT01438073
StatusCompleted
PhasePhase 1
SponsorMassachusetts General Hospital
Enrollment96 participants
DesignInterventional, Na, Single Group, Masking: None
ConditionsHypogonadotropic Hypogonadism; Healthy Postmenopausal Women; Agonadism
Interventionskisspeptin 112-121; GnRH
StartSep 2011
Primary completionApr 2016
Study completionApr 2016
Results postedNot yet
Registry last updatedJul 11, 2022

Compounds on this site that cite this trial

What the registry says the trial is about

The investigators are looking for subjects to complete a study on the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that tells the body to produce other reproductive hormones. However, giving someone a continued amount of kisspeptin over a period of time can have the opposite effect and tell the body to, for a short time, stop making hormones needed for reproduction. By giving 24-hour infusions of kisspeptin, the investigators hope to learn more about the role kisspeptin has in the way bodies function normally and the role it has in conditions that affect the reproductive system.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion24 hours

2 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 3, 2026. See the trial changes feed for what has changed recently.